Palonosetron 0.25 Mg Injection Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 0.25 mg/5 mL vial

Reference Brands: Posfrea (USA)

Category: Oncology Cancer Care

Palonosetron Injection 0.25 mg/5 mL is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). Approved in both the U.S. and EU, it is particularly effective for patients undergoing highly emetogenic chemotherapy. Available in a single-dose vial for IV administration, it plays a key role in oncology B2B distribution, helping oncology centers manage chemotherapy side effects and improve patient comfort. Palonosetron 0.25 mg Injection is available in Injection and strengths such as 0.25 mg/5 mL vial. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Palonosetron 0.25 mg Injection is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Palonosetron 0.25 mg Injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Palonosetron Injection 0.25 mg/5 mL is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It is particularly effective for patients undergoing highly emetogenic chemotherapy regimens. Approved in both the U.S. (under the brand name Aloxi) and the EU, Palonosetron is available as a single-dose 0.25 mg/5 mL vial for IV administration. This drug is essential in oncology B2B distribution, helping oncology centers and hospitals manage the side effects of chemotherapy, ensuring better patient outcomes by reducing nausea and vomiting after treatment.